Live feed17:00:00·45dPRReleasevia QuantisnowArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual MeetingByQuantisnow·Wall Street's wire, on your screen.AVBP· ArriVent BioPharma Inc.Health Care
